Meda AB Sustainability Profile
Meda AB, a prominent player in the pharmaceutical industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 1999, the company has established itself as a leader in the development and marketing of generic and specialty pharmaceuticals, focusing on areas such as pain management, respiratory health, and dermatology. Meda's core offerings include a diverse range of high-quality medications that are distinguished by their efficacy and patient-centric formulations. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position and expanded its product portfolio. With a commitment to innovation and quality, Meda AB continues to be recognised for its contributions to healthcare, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does Meda AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Meda AB's score of 48 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Meda AB, headquartered in Sweden (SE), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Viatris Inc., which may influence its climate commitments and reporting practices. As part of its corporate family relationship with Viatris Inc., Meda AB's climate initiatives and targets are likely aligned with those set by its parent company. However, no specific reduction targets or climate pledges have been detailed for Meda AB itself. The absence of documented reduction initiatives suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. Meda AB's commitment to sustainability and climate action may be informed by Viatris Inc.'s broader environmental goals, which could include adherence to frameworks such as the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, without specific data or targets from Meda AB, it is challenging to provide a comprehensive overview of its carbon emissions and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 302,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Meda AB's Industry?
How Carbon Intensive is Meda AB's Location?
Meda AB's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Meda AB has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
